{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:46:01Z","timestamp":1767991561544,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bestpracticeobgyn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.bpobgyn.2014.04.020","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T18:16:10Z","timestamp":1408558570000},"page":"225-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Management of diabetes and pregnancy \u2013 When to start and what pharmacological agent to choose?"],"prefix":"10.1016","volume":"29","author":[{"given":"Liran","family":"Hiersch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yariv","family":"Yogev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2014.04.020_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ajog.2004.11.039","article-title":"Gestational diabetes: the consequences of not treating","volume":"192","author":"Langer","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib2","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa042973","article-title":"Effect of treatment of gestational diabetes mellitus on pregnancy outcomes","volume":"352","author":"Crowther","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib3","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1056\/NEJMoa0902430","article-title":"A\u00a0multicenter, randomized trial of treatment for mild gestational diabetes","volume":"361","author":"Landon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib4","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0002-9378(94)70097-4","article-title":"Intensified versus conventional management of gestational diabetes","volume":"170","author":"Langer","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/GRF.0b013e3182a8e07d","article-title":"Glycemic targets for the optimal treatment of GDM","volume":"56","author":"Langer","year":"2013","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/01.AOG.0000433006.09219.f1","article-title":"Gestational diabetes mellitus","volume":"122","author":"Practice Bulletin No. 137","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/AOG.0b013e318203ebe0","article-title":"The relationship between maternal glycemia and perinatal outcome","volume":"117","author":"Landon","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3109\/14767058.2012.670413","article-title":"Measuring glucose exposure and variability using continuous glucose monitoring in normal and abnormal glucose metabolism in pregnancy","volume":"25","author":"Mazze","year":"2012","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity","volume":"13","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2337\/diab.33.9.838","article-title":"Mechanism of improvement in glucose metabolism after chronic glyburide therapy","volume":"33","author":"Simonson","year":"1984","journal-title":"Diabetes"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib11","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/diab.36.11.1320","article-title":"Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects","volume":"36","author":"Groop","year":"1987","journal-title":"Diabetes"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.14.8.724","article-title":"Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans","volume":"14","author":"Groop","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib13","first-page":"72","article-title":"Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals","volume":"7","author":"DeFronzo","year":"1984","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJM199201023260104","article-title":"Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance","volume":"326","author":"Mitrakou","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198805123181903","article-title":"Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus","volume":"318","author":"Polonsky","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib16","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2337\/diacare.13.9.992","article-title":"Natural history of beta-cell dysfunction in NIDDM","volume":"13","author":"Leahy","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib17","first-page":"1712","article-title":"The pharmacologic basis of therapeutics","author":"Goodman and Gillman","year":"1996"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-2007-979835","article-title":"The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus","volume":"28","author":"Clark","year":"1996","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/(SICI)1096-9136(199707)14:7<556::AID-DIA389>3.0.CO;2-6","article-title":"Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients","volume":"14","author":"van der Wal","year":"1997","journal-title":"Diabet Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/ajhp\/54.8.893","article-title":"Metformin hydrochloride: an antihyperglycemic agent","volume":"54","author":"Klepser","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM199508313330903","article-title":"Metabolic effects of metformin in non-insulin-dependent diabetes mellitus","volume":"333","author":"Stumvoll","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib22","first-page":"1326","article-title":"Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats","volume":"47","author":"Buckingham","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib23","series-title":"Therapy for diabetes mellitus and related disorders","first-page":"181","article-title":"Thiazolidinediones","author":"Lebovitz","year":"1998"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2337\/diacare.18.6.817","article-title":"Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study","volume":"18","author":"Coniff","year":"1995","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0889-8529(05)70266-8","article-title":"alpha-Glucosidase inhibitors","volume":"26","author":"Lebovitz","year":"1997","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM198405033101807","article-title":"Biologic and clinical importance of proinsulin","volume":"310","author":"Robbins","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2337\/diab.33.5.486","article-title":"C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations","volume":"33","author":"Polonsky","year":"1984","journal-title":"Diabetes"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1172\/JCI108275","article-title":"The essentiality of insulin and the role of glucagon in regulating glucose utilization and production during strenuous exercise in dogs","volume":"57","author":"Vranic","year":"1976","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2337\/diacare.11.4.311","article-title":"Hyperglycemia after intense exercise in IDDM subjects during continuous subcutaneous insulin infusion","volume":"11","author":"Mitchell","year":"1988","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF00427978","article-title":"Circadian variations of blood sugar and plasma insulin levels in man","volume":"5","author":"Malherbe","year":"1969","journal-title":"Diabetologia"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF01059088","article-title":"Modeling absorption kinetics of subcutaneous injected soluble insulin","volume":"17","author":"Mosekilde","year":"1989","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM198908103210605","article-title":"The physiologic replacement of insulin. An elusive goal","volume":"321","author":"Zinman","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/dtb.1997.35857","article-title":"Humalog\u2013a new insulin analogue","volume":"35","year":"1997","journal-title":"Drug Ther Bull"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2337\/diacare.25.5.883","article-title":"Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes","volume":"25","author":"Hermansen","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2337\/diab.43.3.396","article-title":"[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin","volume":"43","author":"Howey","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/BF00417697","article-title":"Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM","volume":"37","author":"Torlone","year":"1994","journal-title":"Diabetologia"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/(SICI)1096-9136(199607)13:7<683::AID-DIA144>3.0.CO;2-1","article-title":"Time-action profile of the insulin analogue B28Asp","volume":"13","author":"Heinemann","year":"1996","journal-title":"Diabet Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib38","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2337\/diacare.25.5.876","article-title":"Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes","volume":"25","author":"Lindholm","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/jmf.12.6.365.375","article-title":"New and future diabetes therapies: are they safe during pregnancy?","volume":"12","author":"Preece","year":"2002","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib40","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1172\/JCI111764","article-title":"Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta","volume":"75","author":"King","year":"1985","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/BF00400229","article-title":"Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor","volume":"36","author":"Grant","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","article-title":"Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use","volume":"49","author":"Kurtzhals","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib43","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1073\/pnas.78.7.4588","article-title":"Transplacental passage of insulin complexes to antibody","volume":"78","author":"Bauman","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJM199008023230505","article-title":"Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. Its role in fetal macrosomia","volume":"323","author":"Menon","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib45","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2337\/diacare.22.9.1422","article-title":"Metabolic and immunologic effects of insulin lispro in gestational diabetes","volume":"22","author":"Jovanovic","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib46","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.2337\/diacare.26.5.1390","article-title":"Transfer of insulin lispro across the human placenta: in\u00a0vitro perfusion studies","volume":"26","author":"Boskovic","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3949\/ccjm.66.5.293","article-title":"New insulin replacement technologies: overcoming barriers to tight glycemic control","volume":"66","author":"Leslie","year":"1999","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib48","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","article-title":"Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901\/3002 Study Group","volume":"23","author":"Yki-Jarvinen","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib49","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/dom.12098","article-title":"The use of insulin analogues in pregnancy","volume":"15","author":"Lambert","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/10915810290096315","article-title":"Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits","volume":"21","author":"Hofmann","year":"2002","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib51","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0378-5122(02)00016-6","article-title":"IGF-1 in gynaecology and obstetrics: update 2002","volume":"41","author":"Druckmann","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/14767058.2013.799650","article-title":"A\u00a0randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes","volume":"27","author":"Hod","year":"2014","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib53","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.2337\/dc11-2264","article-title":"Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes","volume":"35","author":"Mathiesen","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib54","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0095-5108(18)30389-0","article-title":"Alternative therapies for the management of gestational diabetes","volume":"20","author":"Mulford","year":"1993","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib55","first-page":"635","article-title":"Management of diabetes mellitus and pregnancy: a survey of obstetricians and maternal-fetal specialists","volume":"75","author":"Landon","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib56","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc11-S011","article-title":"Standards of medical care in diabetes\u20132011","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib57","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc07-s225","article-title":"Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus","volume":"30","author":"Metzger","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/jmf.12.6.362.364","article-title":"A\u00a0consensus report of the Diabetes in Pregnancy Study Group of North America Conference, Little Rock, Arkansas, May 2002","volume":"12","author":"Reece","year":"2002","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib59","first-page":"B91","article-title":"Maternal glycemic criteria for insulin therapy in gestational diabetes mellitus","volume":"21","author":"Langer","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib60","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0029-7844(98)00547-X","article-title":"Dietary therapy for gestational diabetes: how long is long enough?","volume":"93","author":"McFarland","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-2007-994138","article-title":"Early treatment of gestational diabetes reduces the rate of fetal macrosomia","volume":"14","author":"Shushan","year":"1997","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8227(88)80071-8","article-title":"Fetal outcome in gestational diabetes with elevated amniotic fluid insulin levels. Dietary versus insulin treatment","volume":"5","author":"Weiss","year":"1988","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000301081","article-title":"[Amniotic fluid insulin levels versus mean maternal blood glucose levels in gestational diabetes mellitus: an analysis of the neonatal outcome]","volume":"49","author":"Holzapfel-Bauer","year":"2009","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib64","first-page":"B99","article-title":"Utility of fetal measurements in the management of gestational diabetes mellitus","volume":"21","author":"Buchanan","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib65","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2337\/diacare.24.11.1904","article-title":"A\u00a0randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia","volume":"24","author":"Kjos","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11892-009-0044-3","article-title":"The use of oral antidiabetic medications in gestational diabetes mellitus","volume":"9","author":"Paglia","year":"2009","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib67","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM200010193431601","article-title":"A\u00a0comparison of glyburide and insulin in women with gestational diabetes mellitus","volume":"343","author":"Langer","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib68","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1345\/aph.1K577","article-title":"Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes","volume":"42","author":"Moretti","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/AOG.0b013e318190a459","article-title":"Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review","volume":"113","author":"Nicholson","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib70","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ajog.2004.07.011","article-title":"Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome","volume":"192","author":"Langer","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib71","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/GRF.0b013e3182a8e0a5","article-title":"Oral agents for the management of gestational diabetes","volume":"56","author":"Berggren","year":"2013","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib72","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy","volume":"43","author":"Velazquez","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib73","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","article-title":"Metformin versus insulin for the treatment of gestational diabetes","volume":"358","author":"Rowan","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib74","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2337\/dc11-0660","article-title":"Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age","volume":"34","author":"Rowan","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib75","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.diabres.2012.09.031","article-title":"Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial","volume":"98","author":"Niromanesh","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib76","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejogrb.2011.11.018","article-title":"Introduction of metformin for gestational diabetes mellitus in clinical practice: has it had an impact?","volume":"160","author":"Gandhi","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib77","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.metabol.2013.06.006","article-title":"Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review","volume":"62","author":"Lautatzis","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib78","doi-asserted-by":"crossref","first-page":"e64585","DOI":"10.1371\/journal.pone.0064585","article-title":"Metformin vs insulin in the management of gestational diabetes: a meta-analysis","volume":"8","author":"Gui","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib79","first-page":"24","article-title":"Optimal insulin delivery for the pregnant diabetic patient","volume":"5","author":"Jovanovic","year":"1982","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib80","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0002-9378(88)80020-6","article-title":"Pregestational diabetes: insulin requirements throughout pregnancy","volume":"159","author":"Langer","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib81","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0002-9378(87)80026-1","article-title":"Gestational diabetes: insulin requirements in pregnancy","volume":"157","author":"Langer","year":"1987","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib82","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/AOG.0b013e31823974e2","article-title":"Gestational diabetes mellitus","volume":"118","author":"Landon","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib83","first-page":"99","article-title":"Premixed insulin aspart 30 (Biasp 30) vs. premixed human insulin 30 (BHI 30) in gestational diabetes mellitus\u2013a pilot study","volume":"58","author":"Balaji","year":"2010","journal-title":"J\u00a0Assoc Physicians India"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib84","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/qjmed\/94.5.255","article-title":"Insulin lispro and regular insulin in pregnancy","volume":"94","author":"Bhattacharyya","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0301-2115(03)00157-X","article-title":"Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women","volume":"111","author":"Mecacci","year":"2003","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib86","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ecl.2011.12.002","article-title":"Insulin therapy in pregnancy","volume":"41","author":"McElduff","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib87","doi-asserted-by":"crossref","first-page":"649070","DOI":"10.1155\/2012\/649070","article-title":"Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy","volume":"2012","author":"Lepercq","year":"2012","journal-title":"Obstet Gynecol Int"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib88","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/dmrr.1213","article-title":"Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised, controlled trial in type 1 diabetes","volume":"27","author":"Mathiesen","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib89","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1464-5491.2009.02852.x","article-title":"Use of insulin detemir in pregnancy: a report on 10 Type 1 diabetic women","volume":"26","author":"Lapolla","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.bpobgyn.2014.04.020_bib90","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1464-5491.2012.03580.x","article-title":"Audit of insulin detemir in pregnancy: a retrospective case series","volume":"29","author":"Shenoy","year":"2012","journal-title":"Diabet Med"}],"container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693414001680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693414001680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:42:13Z","timestamp":1565743333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693414001680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1521693414001680"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2014.04.020","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of diabetes and pregnancy \u2013 When to start and what pharmacological agent to choose?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2014.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}